Sandra Fernández Rodríguez- Master of Neuroscience
- PostDoc Position at University of Valencia
Sandra Fernández Rodríguez
- Master of Neuroscience
- PostDoc Position at University of Valencia
About
8
Publications
646
Reads
How we measure 'reads'
A 'read' is counted each time someone views a publication summary (such as the title, abstract, and list of authors), clicks on a figure, or views or downloads the full-text. Learn more
60
Citations
Introduction
Current institution
Additional affiliations
September 2018 - present
Position
- PhD Student
Description
- My research is focused on the development of new pharmacotherapies for the treatment of relapse in alcoholism.
February 2017 - February 2018
Position
- Master's Student
Description
- I worked on a project focused on the genetic characterization of the rare disease Neurodegeneration with Brain Iron Accumulation (NBIA)
Education
September 2016 - July 2017
September 2012 - July 2016
Publications
Publications (8)
The alcohol use disorder (AUD) is a complex, chronic pathology with a high relapse rate. Resumption to alcohol intake after a long period of abstinence is one of the most severe handicaps of this pathological condition. Consequently, in the last decade, a wealth of studies has focused on the neurobiological mechanisms involved in various phases of...
Rationale
Opioid drugs indirectly activate dopamine (DA) neurons in the ventral tegmental area (VTA) through a disinhibition mechanism mediated by mu opioid receptors (MORs) present both on the GABA projection neurons located in the medial tegmental nucleus/tail of the VTA (RMTg/tVTA) and on the VTA GABA interneurons. It is well demonstrated that e...
Introduction: Clinical studies on the effectiveness of Baclofen in alcohol use disorder (AUD) yielded mixed results possibly because of differential effects of the enantiomers and sex-related differences. Here we examined the effect of the different Baclofen enantiomers on alcohol intake and on evoked dopamine release in the core of the nucleus acc...
Rationale
Using a preclinical model based on the Alcohol Deprivation Effect (ADE), we have reported that N-Acetylcysteine (NAC) can prevent the relapse-like drinking behaviour in long-term ethanol-experienced male rats.
Objectives
To investigate if chronic ethanol intake and protracted abstinence affect several glutamate transporters and whether N...
Rationale
Accumulating evidence suggests that chronic alcohol consumption is associated with excessive oxidative damage and neuroinflammatory processes and these events have been associated to early alcohol withdrawal. In the present research we wonder if brain oxidative stress and neuroinflammation remains altered during prolonged withdrawal situa...
N-acetylcysteine (NAC) is a prodrug that is Marketed as a Mucolytic agent and used for the treatment of acetaminophen overdose. Over the last few decades, evidence has been gathered that suggests the potential use of NAC as a new pharmacotherapy for alcohol use disorder (AUD), although its Mechanism of action is already being debated. In this paper...
Alcohol use disorders are chronic and highly relapsing disorders, thus alcoholic patients have a high rate of recidivism for drug use even after long periods of abstinence. The literature points to the potential usefulness of N‐acetylcysteine (NAC) in the management of several substance use disorders probably due to its capacity to restore brain ho...
FBXO7 is implicated in the ubiquitin–proteasome system and parkin-mediated mitophagy. FBXO7defects cause a levodopa-responsive parkinsonian-pyramidal syndrome(PPS). Methods: We investigated the disease molecular bases in a child with PPS and brain iron accumulation. Results: A novel homozygous c.368C>G (p.S123*) FBXO7 mutation was identified in a c...
